Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genomically matched targeted therapy for BRAF/NRAS wild-type metastatic melanoma
ACTRN12616001187437Phase 2Not yet recruiting
- Sponsor
- Melanoma Institute Australia
- Start
- Dec 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus, bortezomib, cabozantinib, ceritinib, crizotinib and 15 more in melanoma (2 arms), sponsored by Melanoma Institute Australia. Primary endpoints: Frequency of genetic aberrations in BRAF/NRAS wild-type metastatic melanoma and Proportion receiving matched targeted therapy. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
everolimusbortezomibcabozantinibceritinibcrizotinib
03
Conditions
melanoma
Beyond the preview
Go deeper on ACTRN12616001187437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001187437.